DITRAP introduces RA0127, a first-in-class soluble glycopolymer that selectively removes natural anti-αGal antibodies. These antibodies, paradoxically, enhance Gram-negative infections and create an “immune trap” in critically ill patients. By disarming this trap, RA0127 strengthens host immunity without immunosuppression, restoring the body’s ability to clear even multidrug-resistant pathogens. A completed Phase 1 trial confirmed safety and demonstrated over 60% reduction of target antibodies after a single low dose, providing a strong foundation for Phase 2 evaluation.
To maximise precision and responsible clinical application, DITRAP integrates an AI-based stratification tool that identifies high-risk patients within 48 hours of admission and enables targeted therapy. Alongside, comprehensive health economic modelling and Health Technology Assessment (HTA) will ensure robust evaluation of clinical benefit, cost-effectiveness and adoption across European healthcare systems.
From advancing scientific knowledge to improving patient outcomes, DITRAP’s objectives provide the roadmap for developing and validating a novel approach to combat infections in critically ill patients and address the growing challenge of antimicrobial resistance.
Eight interlinked work packages cover project management, manufacturing and regulatory preparation, AI model development, clinical trial delivery, immunological analysis, health technology assessment, communication and exploitation, and ethics requirements.
DITRAP aims to advance RA0127 from TRL 7 to TRL 9, support faster access to innovative therapies and contribute to lower infection rates, reduced antibiotic use, shorter ICU stays and more sustainable healthcare.
